Advertisement
Regeneron Pharma Expects Q4 Results To Include $24 Mln In Acquired In-process R&D Charge
(RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) said Monday it currently expects that its financial results for the second quarter 2024 will include an acquired in-process research and development charge of approximately $24 million on a pre-tax basis.
This charge relates to up-front payments, as well as a premium on equity securities purchased, in connection with collaboration and licensing agreements.
This charge is expected to negatively impact each of GAAP and non-GAAP net income per share for the second quarter 2024 by approximately $0.18.
read more
Regeneron Pharma Q2 Results Top Estimates - Update
Biotechnology company Regeneron Pharmaceuticals, Inc. (REGN) reported on Thursday that net income for the second quarter increased to $1.43 billion or $12.41 per share from $968 million or $8.50 per share in the prior-year quarter.
RTTNews
|
439 일 전
Regeneron Says CHMP Recommends Conditional Marketing Authorization For Odronextamab In EU
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of odronextamab to treat adults with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy.
RTTNews
|
473 일 전
Regeneron Pharma Q4 Results Top Estimates - Update
Regeneron Pharmaceuticals, Inc. (REGN) reported on Friday that net income for the fourth quarter declined 3 percent to $1.16 billion or $10.19 per share from $1.20 billion or $10.50 per share in the prior-year quarter.
RTTNews
|
620 일 전
Regeneron Completes Acquiring Sanofi's Stake In Libtayo
Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that it has completed the acquisition of French drug major Sanofi's (SNYNF, SNY) stake in Libtayo (cemiplimab), providing Regeneron with exclusive worldwide development, commercialization, and manufacturing rights to the medicine originally discovered in Regeneron's laboratories. The intent to purchase Libtayo was announced on June 2, 2022.
RTTNews
|
1201 일 전
Apple To Expand Renewable Energy Projects Across Europe
Tech major Apple Inc. has unveiled a significant expansion of its renewable energy projects across Europe to boost energy capacity to match the electricity customers use to power its products. The new solar and wind projects, all enabled by Apple, will add 650 megawatts or MW of renewable energy capacity in various European countries, including Greece, Italy, Latvia, Poland, and Romania.
RTTNews
|
18 분 전
Yen Rises Against Majors
The Japanese yen strengthened against other major currencies in the Asian session on Tuesday.
RTTNews
|
21 분 전
Pound Slides Against Majors
The British pound weakened against other major currencies in the European session on Tuesday.
RTTNews
|
28 분 전
Canadian Dollar Drops Against Most Majors
The Canadian dollar weakened against most major currencies in the Asian session on Tuesday.
The Canadian dollar fell to a 6-month low of 1.4055 against the U.S. dollar and a 4-day low of 1.6283 against the euro, from yesterday's closing quotes of 1.4040 and 1.6237, respectively.
RTTNews
|
37 분 전
